

To,  
The General Manager  
BSE Limited  
Corporate Relation Department  
Phiroze Jeejeebhoy Towers,  
14<sup>th</sup> Floor, Dalal Street,  
Fort, Mumbai- 400 001  
Scrip Code: **524731**.

Reference: **Buyback of equity shares of Jenburkt Pharmaceuticals Limited ("Company") from the open market through BSE Limited in accordance with the SEBI (Buy-Back of Securities) Regulations, 2018 ("Buyback Regulations")**.

Subject : **Submission of details of fifth and final lot of extinguishment of shares bought back pursuant to provisions of Regulation 21 read with Regulation 11 of the Buyback Regulations.**

Dear Sir/ Madam,

Pursuant to the Public Announcement dated 03<sup>rd</sup> December, 2022 published on 05<sup>th</sup> December, 2022, the Company commenced buyback of equity shares of face value of ₹ 10/- each fully paid-up (the "Equity Shares") from its shareholders starting from 13<sup>th</sup> December, 2022.

In accordance with the provisions of Regulation 24(iv) of the Buyback Regulations, this is to inform that the Company has completed the fifth lot of extinguishment of 22,667 (Twenty Two Thousand Six Hundred Sixty Seven Only) equity shares bought back under the Buy-back during the period from 01<sup>st</sup> March, 2023 to 24<sup>th</sup> March, 2023. In connection with the same, we are submitting herewith details of fifth and final lot of extinguishment of shares along with the debit confirmation letter received from the Central Depository Services Limited as **Annexure A** for your records. The Reconciliation of Share Capital of the Company (Pre and Post extinguishment) is as under:

Reconciliation of Share Capital of the Company (Pre and Post extinguishments) as on 29/03/2023			
Sr. No.	Particulars	No. of shares	Share Capital (in ₹)
A	Paid up Equity shares capital (Prior to buyback)	45,89,378	4,58,93,780
B	Cumulative Equity Shares Extinguished in lot 1, 2, 3 and 4	(1,53,411)	(15,34,110)
C	Equity Shares bought back from 01 <sup>st</sup> March, 2023 to 24 <sup>th</sup> March, 2023 extinguished on 29 <sup>th</sup> March, 2023. (05 <sup>th</sup> and final lot)	(22,667)	(2,26,670)
D	Paid up Equity share capital (Post Extinguishments of 05 <sup>th</sup> and final lot) (D=A-B-C)	44,13,300	4,41,33,000

- The buyback of equity shares of the Company was closed with effect from closing of trading hours as on 24<sup>th</sup> March, 2023.

We confirm that above Equity Shares of the Company were extinguished in compliance with the provisions of Regulation 21 read with Regulation 11 of the Buy-back Regulations.

**For Jenburkt Pharmaceuticals Limited,**

Ashish R Shah  
Company Secretary and Compliance Officer.

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Encl.: a/a



# Central Depository Services (India) Limited



March 31 , 2023

CDSL/OPS/IPO-CA/2022-23/CA-504007.005

**The Company Secretary,  
Jenburkt Pharmaceuticals Limited**  
Nirmala Apartments  
93, Jayprakash Road  
Andheri West Mumbai, Maharashtra,  
India - 400058

Dear Sir,

**Sub:- Buyback**

This is to inform you that the file uploaded by you / your RTA for the above-mentioned purpose, has been successfully processed at **Central Depository Services (India) Limited**. The details of the same are as follows:

CA Seq. No.	ISIN	Type Of Security	Date Effected	No. of Records	No. of Securities
504007.005	Debit ISIN INE354A01013	Jenburkt Pharmaceuticals Limited # Equity Shares	29-Mar-2023	1	22667

Thanking you,

Yours faithfully,  
For **Central Depository Services (India) Limited**

**Vinifer T Kodia**  
Asst Vice President – Operations

c.c **Bigshare Services Private Limited**

Digitally signed by VINIFER TEHMTON KODIA  
Date: 2023.03.31 12:13:51 +05:30

Regd. Office : Marathon Futurex, Mafatlal Mill Compounds, A-Wing, 25th floor, N M Joshi  
Marg, Lower Parel (East), Mumbai - 400013.

Phone: 91 - 22-2302-3333 • Fax: 91 - 22 - 2300 2035/2036. CIN: L67120MH1997PLC112443

Website : [www.cdslindia.com](http://www.cdslindia.com)